News | June 02, 2015

CT Angiography Links Arterial Plaque with Diabetes, Blood Pressure, Cholesterol

Soft plaque assessments may offer disease diagnosis beyond calcium scoring

CT angiography, CCTA, arterial plaque, calcification, calcium scoring

June 2, 2015 — Non-calcified arterial plaque is associated with diabetes, high systolic blood pressure and elevated “bad” cholesterol levels in asymptomatic individuals, according to a new study published online in the journal Radiology.

Coronary artery disease (CAD) is the leading cause of death in men and women worldwide, accounting for 17 million deaths annually. Current treatment strategies focus on cardiovascular risk and serum cholesterol levels rather than direct assessment of extent of disease in the coronary arteries.

Plaque that forms in the arterial walls can restrict blood flow and in some cases rupture, leading to potentially fatal heart attacks. There is considerable evidence that calcified, or stable, plaque is less prone to rupture than non-calcified, or soft, plaque. Intravascular ultrasound can quantify non-calcified and calcified coronary artery plaque, but it is invasive and unsuitable for screening purposes. Coronary artery calcium (CAC) scoring with computed tomography (CT), a common noninvasive option, measures how much calcified plaque a person has, but it doesn’t measure non-calcified plaque, and that’s the component that tends to be dangerous. Despite treatment for hypercholesterolemia (high levels of cholesterol in the blood), CAC scores often paradoxically increase. Thus, researchers have searched for other plaque measures that can identify treatment response.

“Most information to date about coronary artery disease and cardiovascular risk factors in asymptomatic individuals has been derived from calcium scoring,” said the study’s lead author, David A. Bluemke, M.D., Ph.D., from the National Institutes of Health (NIH) Clinical Center. “We hypothesized that risk factors for the presence of non-calcified plaque may differ from those for calcified plaque.”

Coronary computed tomography angiography (CCTA) has emerged as a viable screening option for plaque, including non-calcified plaque. CCTA can capture the full anatomic map of the coronary arteries in a single heartbeat with low radiation dose and provide a complete picture of the total amount of plaque throughout the arteries of the heart.

For the study, Bluemke and colleagues used CCTA to assess the relationship between calcified and non-calcified coronary plaque burden in the coronary arteries and cardiovascular risk factors in low- to moderate-risk asymptomatic individuals.

The researchers recruited 202 asymptomatic men and women over age 55 who were eligible for statin therapy. CCTA was performed using a 320-detector row CT scanner and an intravenous contrast agent. Coronary wall thickness/plaque was evaluated, and analysis was performed to determine the relationship between risk factors and plaque.

Controlling for all risk factors, total coronary plaque index was greater in men than in women. Non-calcified plaque index was significantly associated with greater systolic blood pressure, diabetes and elevated low-density lipoprotein (LDL) cholesterol level.

“These results highlight the potential of CCTA in quantifying plaque burden to assess progression or regression of coronary artery disease in low- to moderate-risk individuals,” Bluemke said.

For more information: www.radiology.rsna.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now